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B
rain arteriovenous malformations (AVMs) cause life-threatening intracranial hemorrhage, but brain AVM (bAVM) pathobiology is poorly understood. Previously, we induced a bAVM phenotype in adult mice by focal pan-cellular Alk1 gene deletion and vascular endothelial growth factor (VEGF) stimulation. 1 Alk1 is predominantly expressed in the arterial endothelial cell (EC). 2 We tested the hypotheses that deletion of Alk1 in EC is sufficient to cause bAVM after angiogenic stimulation, and that increased growth of Alk1-deficient EC is a key mechanism underlying bAVM development.
Methods
Detailed methods are described in the online-only Data Supplement. Experimental procedures for using laboratory animals were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco and conformed to the National Institutes of Health Guidelines for the care and use of animals in research.
Alk1 2f/2f mice (Alk1 exons 4-6 flanked by loxP sites) 3 were bred with Pdgfb-iCreER mice that express tamoxifen-inducible cre recombinase (iCreER) in EC. 4 EC-Alk1 deletion was induced 5 by intraperitoneal injection of tamoxifen 14 days after intrabrain injection of adeno-associated viral serotype 1-packaged adeno-associated viral-VEGF with cytomegalovirus promoter driving VEGF expression. Mice with NG2 promoter (NG2-iCreER) driving cre expression were used to induce pericyte-Alk1 deletion. Vascular morphology was analyzed using latex casting and immunostaining 10 days after tamoxifen administration. EC proliferation and dysplasia index were quantified. Experimental design and groups are shown in Figure 1 . Data are mean±SD. Background and Purpose-In humans, activin receptor-like kinase 1 (Alk1) deficiency causes arteriovenous malformations (AVMs) in multiple organs, including the brain. Focal Alk1 pan-cellular deletion plus vascular endothelial growth factor stimulation induces brain AVMs in the adult mouse. We hypothesized that deletion of Alk1 in endothelial cell (EC) alone plus focal vascular endothelial growth factor stimulation is sufficient to induce brain AVM in the adult mouse. Methods-Focal angiogenesis was induced in the brain of 8-week-old Pdgfb-iCreER;Alk1 2f/2f mice by injection of adenoassociated viral vectors expressing vascular endothelial growth factor. Two weeks later, EC-Alk1 deletion was induced by tamoxifen treatment. Vascular morphology was analyzed, and EC proliferation and dysplasia index (number of vessels with diameter >15 μm per 200 vessels) were quantified 10 days after tamoxifen administration. Results-Tangles of enlarged vessels resembling AVMs were present in the brain angiogenic region of tamoxifentreated Pdgfb-iCreER;Alk1 2f/2f mice. Induced brain AVMs were marked by increased dysplasia index (P<0.001) and EC proliferation clustered within the dysplastic vessels. AVMs were also detected around the ear tag-wound and in other organs. 
Results

EC-Alk1 Deletion Resulted in AVM in the Brain Angiogenic Region and Other Organs
Conclusions-Deletion of
EC Proliferation Increased in bAVM
Discussion
Previously, we reported that injection of adeno-associated viral-VEGF into the brain of adult Alk1 +/-mice induces a capillary level of dysplasia, 6 which served as a surrogate model for bAVM until we developed a macroscopic level of a bAVM model through focal homozygous Alk1 deletion plus VEGF stimulation. 1 In that model, an adenoviral vector that has cytomegalovirus promoter driving cre expression (Ad-Cre) was used to induce focal pan-cellular Alk1 deletion. 1 Here, we show that deletion of Alk1 in adult EC results in a bAVM phenotype similar to that in the pan-cellular Alk1 deletion model. Both have macrophage infiltration and microhemorrhage. 7 EC-specific Alk1 deletion in the adult mouse has also resulted in AVM in the small intestine and lung and around the skin 
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wound, which recapitulated the phenotype of global Alk1 deletion in adult mice. 5 Thus, deletion of Alk1 in adult EC is sufficient to induce AVMs.
SM22α-Cre-driven Alk1 deletion has been reported to result in brain and spinal cord AVMs, 8 suggesting that loss of Alk1 from pericytes/vascular smooth muscle cells can cause AVMs. In contrast, we find that conditional deletion of Alk1 in adult pericytes did not trigger AVMs in any organ, around the ear-tag wound, or in the VEGF-stimulated brain. As revealed by Rosa-LacZ cre reporters, SM22α promoter driving cre expression results in nonspecific recombination in EC lineage. 8 Therefore, we propose that Alk1 deletion in pericytes alone is not sufficient and that gene deletion in EC is required to initiate AVM development.
We found that deletion of Alk1 in ECs in the adult brain increased EC proliferation in response to VEGF stimulation. Although the expression of Ai14 reporter indicated that cre was activated in ECs of all vessels in the angiogenic region, only a few dysplasia vessels were formed. The dysplastic vessels have more proliferating ECs than the surrounding normal capillaries. As it is statistically unlikely that the dominance of the proliferating cells in dysplastic vessels is the result of multiple independent cre recombination events, we propose that ECs with homozygous Alk1 deletion undergo clonal expansion and have a higher proliferation rate than wildtype EC or Alk1 +/-EC, which results in unevenly enlarged abnormal vessels. This hypothesis needs to be further validated.
In summary, deletion of Alk1 in EC leads to increased focal EC proliferation during brain angiogenesis and de novo AVM development. Knowledge of the importance of EC in AVM development will help in understanding AVM pathogenesis and in designing specific therapies.
ONLINE SUPPLEMENT
De novo cerebrovascular malformation in the adult mouse after endothelial Alk1 deletion and angiogenic stimulation
Supplemental Methods
Animal Breeding and Modeling
For induction of endothelial Alk1 deletion, we crossbred Alk1 2f/2f (exons 4-6 flanked by loxP sites) mice 1 with mice expressing a tamoxifen (TM)-inducible Cre recombinase (iCreER) driven by Pdgfb promoter (Pdgfb-iCreER).
2 Pdgfb is predominately expressed in endothelial cells; therefore, tamoxifen (TM) treatment will induce endothelial-Alk1 deletion in PdgfbiCreER;Alk1 2f/2f mice.
Eight-week-old Pdgfb-iCreER;Alk1 2f/2f mice were anesthetized with isoflurane inhalation and placed in a stereotactic frame with a holder (David Kopf Instruments, Tujunga, CA). A burr hole was drilled in the pericranium 2mm lateral to the sagittal suture and 1mm posterior to the coronal suture. Adeno-associated viral vector (AAV)-expressing CMV promoter driving VEGF (AAV-VEGF) 3 was packaged in AAV serotype 1 capside and was stereotactically injected into the basal ganglia of the brain (2X10 9 genome copies). AAV-LacZ was used as control for AAV-VEGF. Two weeks later, a single dose of TM (2.5 mg/25 g body weight) was injected intra-peritoneally (i. p.) and brain samples were collected 10 days later.
For pericyte Alk1 deletion, Alk1
2f/2f mice were crossbred with mice expressing iCreER under the transcriptional control of the NG2 promoter (NG2-iCreER).
4 NG2 is predominately expressed by pericytes, and thus, TM administration will induce pericyte-Alk1 deletion in NG2-iCreER;Alk1 2f/2f mice. TM (4 mg/25g body weight, i.p.) was injected for three consecutive days into 8-week-old NG2-iCreER;Alk1 2f/2f mice. AAV-VEGF (2X10 9 genome copies) was stereotactically injected into the basal ganglia of the brain eight weeks after the TM treatment. Samples were collected eight weeks later.
ROSA26tm14 (CAG-tdTomato) (Ai14) reporter mice that have a loxP flanking stopper before Ai14 coding sequence were used to monitor cre activity.
Latex Perfusion
Mice were deep-anesthetized with isoflurane inhalation. The abdominal and thoracic cavities were opened. Both left and right atria were cut off. Blue latex dye (1 ml, Connecticut Valley Biological Supply Co.) was injected slowly into the left cardiac ventricle using a 25-gauge 5 ml syringe. The brain, ear and intestine were harvested and fixed with 4% paraformaldehyde overnight. The brain and ear were dehydrated with methanol series and clarified with benzyl alcohol/benzyl benzoate (1:1 ratio). After clarification, the brain was cut coronally and images were taken.
Immunohistochemistry
Ten days after TM injection, brain samples were collected, sectioned and stained as previously described.
4°C overnight with the following primary antibodies: anti-CD31 (1:100, Santa Cruz Biotechnology, CA), anti-ki67 (1:100, abcam, MA), anti-CD68 (1:100, abcam, MA), anti-αSMA (1:1000, Sigma-Aldrich, MO). Alexa Fluor 594-conjugated (1:500), Alexa Fluor 488-conjugated IgG (1:500), and Cy5-conjugated goat anti-rat (1:500, Invitrogen, Carlsbad, CA) were used as secondary antibodies.
BrdU Labeling and Quantification
5-Bromodeoxyuridine (BrdU; Sigma) was injected i.p. daily (100 mg/kg) for 10 days following TM administration. Two sections, 0.5mm apart, per brain within the injection site were chosen for double staining with anti-ERG and anti-BrdU antibodies. Sections were fixed with 4% paraformaldehyde for 5 min, and incubated with anti-ERG (1:100, abcam, MA). Alexa Fluor 488-conjugated IgG (1:500) was used as secondary antibody. After completion of anti-ERG staining, the sections were then treated with 2 mol/L HCl at 37°C for 30 minutes and rinsed in 0.1 mol/L boric acid (pH 8.5) at room temperature for 10 minutes. Sections were incubated overnight with anti-BrdU (1:500, Sigma, MO) primary antibody at 4°C. Fluor 594-conjugated (1:500) was used as secondary antibody. Three images were taken from each section (right and left of, and below the injection site) under a 40X objective (Leica MZFL III microscope, Leica Microsystem, Bannockburn, IL). Both ERG + and BrdU + cells were blind-counted.
